ProCE Banner Activity

2-Drug ART Regimens: Is a Simplified Regimen on the Horizon for Most Patients With HIV?

Clinical Thought
My take on how 2-drug regimens and investigational agents are expanding our options for successful antiretroviral therapy in treatment-naive patients, virally suppressed patients switching regimens, and potentially to patients experiencing virologic failure.

Released: November 05, 2021

Expiration: November 04, 2022

No longer available for credit.

Share

Faculty

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Merck Sharp & Dohme Corp.

ViiV Healthcare

Faculty Disclosure

Primary Author

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV Healthcare and funds for research support from Janssen.